Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)
0.7500 x 15 0.7962 x 5
Pre-market by (Cboe BZX)
0.7998 +0.0687 (+9.40%) 04/11/25 [NASDAQ]
0.7500 x 15 0.7962 x 5
Pre-market 0.7962 -0.0036 (-0.45%) 05:52 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.7600
Day High
0.7998
Open 0.7900
Previous Close 0.7311 0.7311
Volume 226,700 226,700
Avg Vol 517,670 517,670
Stochastic %K 12.22% 12.22%
Weighted Alpha -85.13 -85.13
5-Day Change -0.0203 (-2.48%) -0.0203 (-2.48%)
52-Week Range 0.3975 - 5.4700 0.3975 - 5.4700
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,197
  • Shares Outstanding, K 14,000
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,760 K
  • EBIT $ -27 M
  • EBITDA $ -26 M
  • 60-Month Beta 2.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.41
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -6.34
  • Most Recent Earnings $-2.09 on 11/08/24
  • Next Earnings Date 05/09/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.71
  • Number of Estimates 1
  • High Estimate -0.71
  • Low Estimate -0.71
  • Prior Year -2.02
  • Growth Rate Est. (year over year) +64.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6900 +15.91%
on 04/09/25
Period Open: 1.1900
1.3200 -39.41%
on 03/25/25
-0.3902 (-32.79%)
since 03/11/25
3-Month
0.3975 +101.21%
on 02/12/25
Period Open: 1.6400
3.6499 -78.09%
on 02/13/25
-0.8402 (-51.23%)
since 01/10/25
52-Week
0.3975 +101.21%
on 02/12/25
Period Open: 4.7700
5.4700 -85.38%
on 05/01/24
-3.9702 (-83.23%)
since 04/11/24

Most Recent Stories

More News
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

MBRX : 0.7998 (+9.40%)
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

MBRX : 0.7998 (+9.40%)
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

MBRX : 0.7998 (+9.40%)
Virtual Investor Releases Next Wave of "Top 5 for '25" On-Demand Videos

- Access video webcasts from all participating companies here

AIM : 0.0949 (-19.37%)
SONN : 1.2900 (+4.03%)
MBRX : 0.7998 (+9.40%)
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

TLSA : 0.7901 (+1.29%)
AIM : 0.0949 (-19.37%)
PEPG : 1.1300 (-3.42%)
AEON : 0.4000 (-2.27%)
MBRX : 0.7998 (+9.40%)
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

GRAL : 23.26 (+2.24%)
ADMA : 19.40 (+3.85%)
EXEL : 35.31 (+2.47%)
GLYC : 0.2019 (+3.75%)
MBRX : 0.7998 (+9.40%)
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023

- Live video webcast interactive Q&A with participating companies -

AREC : 0.4810 (+0.75%)
CNSP : 1.3400 (+13.56%)
EVFM : 0.0095 (unch)
XBIO : 2.30 (-3.36%)
PALI : 0.6970 (+2.50%)
NVNO : 2.19 (+3.30%)
GRI : 1.3300 (+9.92%)
MBRX : 0.7998 (+9.40%)
Moleculin to Participate in the Virtual Investor Ask the CEO Conference

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...

MBRX : 0.7998 (+9.40%)
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including...

MBRX : 0.7998 (+9.40%)
Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including...

MBRX : 0.7998 (+9.40%)

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

3rd Resistance Point 0.8529
2nd Resistance Point 0.8263
1st Resistance Point 0.8131
Last Price 0.7998
1st Support Level 0.7733
2nd Support Level 0.7467
3rd Support Level 0.7335

See More

52-Week High 5.4700
Fibonacci 61.8% 3.5323
Fibonacci 50% 2.9337
Fibonacci 38.2% 2.3352
Last Price 0.7998
52-Week Low 0.3975

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar